ECE2021 Eposter Presentations Thyroid (43 abstracts)
Graves’disease and breast cancer: Is there a link
Kawthar El Arbi , Wajdi Safi , Hadj Kacem Faten , Sidina Mohamed Elmoctar , Mohamed Abdellahi Mohamed Ahmed , Dhoha Ben Salah , Nabila Mejdoub , Mouna Mnif & Abid Mohamed
Hedi Chaker Hospital, Department of Endocrinology, Sfax, Tunisia
Intoduction
The link between hyperthyroidism and breast cancer has been the subject of much controversy and literature in the past. It poses a daily clinical problem of information and senological follow-up of thyroid patients. We report our patient’s case.
Observation
A 46-year-old female patient who presented a Graves’ disease diagnosed 10 years ago. She had a moderate vascular goiter and no ocular signs. She presented firstly a severe hyperthyroidism: an elevated FT4 = 82.5 pmol/l (NR = 11–21) and a suppressed TSH = 0.001 UI/l (NR = 04–4). Thyrotropin receptor antibodies (anti-rTSH) were strongly positive at 23.6 IU/l (NR < 2). The patient was treated with Benzylthiouracil for 3 years followed by voluntary interruption of treatment. The patient was later lost to follow-up. Four years later, she had a suspicious nodule in her left breast. The diagnosis of Invasive ductal carcinoma was confirmed. Tumor extension was negative. The procedure was a tumorectomy and lymph node dissection followed by adjuvant radiochemotherapy. The patient then received an antiestrogen for 5 years. The senological evolution was favourable.
Conclusion
Women with hyperthyroidism may be at increased risk of breast cancer. This suggests that in the case of hyperthyroidism, special attention may also need to be paid to breast cancer screening.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more